Next Article in Journal
Anti-SARS-CoV-2 Vaccination Campaign: Risk Perception, Emotional States, and Vaccine Hesitancy in a Sample of Adolescents’ Vaccinated Parents in Southern Italy
Next Article in Special Issue
BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
Previous Article in Journal
Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation
Previous Article in Special Issue
Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study
Article

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis

1
Bamrasnaradura Infectious Diseases Institute, Nonthaburi 11000, Thailand
2
Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
3
School of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
4
Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02215, USA
5
National Center of Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand
6
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
7
Bumrungrad International Hospital, Bangkok 10110, Thailand
*
Authors to whom correspondence should be addressed.
Academic Editors: Noa Berar Yanay and S. Louise Cosby
Vaccines 2022, 10(6), 959; https://doi.org/10.3390/vaccines10060959
Received: 19 April 2022 / Revised: 11 June 2022 / Accepted: 14 June 2022 / Published: 16 June 2022
Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months. View Full-Text
Keywords: COVID-19; SARS-CoV-2; ChAdOx1 nCoV-19; hemodialysis; ESRD; vaccines; immunogenicity; post-infection COVID-19; SARS-CoV-2; ChAdOx1 nCoV-19; hemodialysis; ESRD; vaccines; immunogenicity; post-infection
Show Figures

Figure 1

MDPI and ACS Style

Prasithsirikul, W.; Nopsopon, T.; Phutrakool, P.; Suwanwattana, P.; Kantagowit, P.; Pongpirul, W.; Jongkaewwattana, A.; Pongpirul, K. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. Vaccines 2022, 10, 959. https://doi.org/10.3390/vaccines10060959

AMA Style

Prasithsirikul W, Nopsopon T, Phutrakool P, Suwanwattana P, Kantagowit P, Pongpirul W, Jongkaewwattana A, Pongpirul K. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. Vaccines. 2022; 10(6):959. https://doi.org/10.3390/vaccines10060959

Chicago/Turabian Style

Prasithsirikul, Wisit, Tanawin Nopsopon, Phanupong Phutrakool, Pawita Suwanwattana, Piyawat Kantagowit, Wannarat Pongpirul, Anan Jongkaewwattana, and Krit Pongpirul. 2022. "ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis" Vaccines 10, no. 6: 959. https://doi.org/10.3390/vaccines10060959

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop